Blog

Jessica Lin: Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today

Photo from Jessica Lin/X

Sep 14, 2024, 07:58

Jessica Lin: Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today

Jessica Lin posted on X:

“Pleased to share an updated efficacy, safety, and biomarker analysis of Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today.

NTRK gene fusions are rare (~0.2% in NSCLC) but present across a diverse spectrum of adult and pediatric cancers
Larotrectinib is approved for tumor-agnostic use in patients with TRK fusion-positive cancers as a selective and CNS-active TRK inhibitor
Today we provided updated efficacy and safety data from two clinical trials evaluating larotrectinib in pts with TRK fusion lung cancer after an additional 12 months of follow-up, as well as biomarker data

Among 32 pts included in this analysis, larotrectinib continued to demonstrate robust efficacy with an ORR 66% (and 67% among pts with known CNS metastases!)

median DOR 34 months (f/u 26 mos)
median PFS 22 months (f/u 28 mos)
median OS 39 months (f/u 33 mos)

Responses seen regardless of the NTRK gene involved or the NTRK1-3 fusion partner
Durable responses (10 pts remaining on treatment at data cut-off)
Baseline ctDNA detected NTRK fusions in 6 of 15 pts
If ctDNA negative, may be non-diagnostic, should f/u with tissue NGS!

Larotrectinib is a very well-tolerated drug overall among patients in the clinic, and the updated analysis continues to support this TEAE and TRAE profile consistent with prior reports
Predominantly grade 1/2 AEs
One patient discontinued tx due to TRAE (increased liver)

Must improve biomarker testing to identify patients who can benefit from effective therapeutic agents like Larotrectinib and to increase their reach to patients!
Thankful to all investigators involved in these studies
Most importantly thankful to patients and caregivers.”

Jessica Lin: Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today

Source: Jessica Lin

Jessica J. Lin, MD, is an attending physician at the Center for Thoracic Cancers and the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School.

Dr. Lin’s research focuses on driver oncogene alterations in non-small cell lung cancer and the development of resistance to targeted therapies. She leads clinical trials exploring new targeted therapies and immunotherapies for lung cancer.